Palantir Technologies (PLTR) was easily the biggest winner on the S&P 500 index last year. And with PLTR stock breaking out in last week's strong market rally, the artificial intelligence play is once again leading in 2025. CVS Health (CVS), Newmont Corp. (NEM), Philip Morris International (MO) and VeriSign (VRSN) round an eclectic top-five for the S&P 500.
Meanwhile, the Magnificent Seven — Tesla (TSLA), Meta Platforms (META), Microsoft (MSFT), Apple (AAPL) and Amazon.com (AMZN), Nvidia (NVDA) and Google-parent Alphabet (GOOGL) — are nowhere near the top performers. In fact, these megacap stocks are all down in 2025, some significantly.
The S&P 500 is off 6.1% in 2025.
Palantir stock is up 49.1% in 2025 as of April 25 after spiking 340.5% for all of 204.
The government and commercial data analytics firm surged 20.3% last week. Shares have nearly doubled since hitting 66.12 intraday on April 7. PLTR stock broke out past a 98.17 double-bottom base buy point on Wednesday and continued to power higher. Investors also could view Palantir's chart as a cup base with a 125.41 buy point, according to MarketSurge.
The relative strength line for Palantir stock is at a record high. The RS line, the blue line in the charts provided, tracks a stock's performance vs. the S&P 500.
Palantir earnings growth is strong, with six straight quarters of accelerating revenue growth.
Palantir will report Q1 earnings on May 5.
CVS stock has rallied 45.51% so far this year after tumbling to a 12-year low in late 2024. The drug store giant, pharmacy benefits manager and health insurance giant has been rangebound since breaking out from a cup-with-handle base in late March. CVS stock is currently just below its 50-day line.
CVS earnings have fallen sharply in the past four quarters. Analysts expected EPS growth to return in 2025 and continue next year. Q1 results are due on Thursday.
Newmont stock has jumped 44.9% in 2025, rebounding from an eight-month low at the very end of 2024. Shares have soared this year among with gold prices and other gold stocks. In truth, NEM stock has been a bit of a laggard relative to many other gold stocks that are greatly extended. Newmont stock cleared an early entry on April 10, continuing to work the right side of a cup base. The buy point is 58.72 on a daily chart, but will have a handle after Monday. On a weekly chart, NEM stock has a 57.16 cup-with-handle buy point already.
Newmont earnings have been in the triple digits for four straight quarters, reflecting huge profits from soaring gold prices.
Philip Morris stock has been smoking hot in 2025, up 41.45% through April 25. Tobacco stocks have been strong as a defensive play about Trump tariffs and recession firms. Phillip Morris International also is benefiting from strong growth in smokeless tobacco products. PM stock boasts a 3.17% dividend yield.
Philip Morris stock is greatly extended from an early February earnings gap-up breakout, and is stretched from a more-recent rebound from the 50-day line to clear a range.
Philip Morris earnings have been in the double-digits for the past three quarters, with double-digit growth seen in 20025 and 2026.
Q1 earnings are due on Tuesday.
VeriSign stock has gained 31.8% so far this year.
Shares rebounded from the 50-day line last week, capped by Friday's 8% jump following earnings. That also cleared a massive consolidation going back to 2021.
Growth for the domain name and web security firm has been modest but solid, with Q1's 9% EPS gain and 5% revenue rise both slight increases from Q4.
The Magnificent Seven has been anything but in 2025. All of them are lagging the S&P 500, dragging down the benchmark index. Meta stock and Microsoft are down 6.5% and 7%, respectively. The other five are down more than 10%. Tesla stock has lost 29.4% this year, even with last week's 18.1% surge.
Microsoft stock and Meta Platforms report Tuesday night. Apple stock and Amazon are due late Thursday.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。